Dr. Lal Pathlabs
Ticker > Company >

Dr. Lal Pathlabs share price

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB BSE: 539524 SECTOR: Hospital & Healthcare Services  248k   1k   317

2750.00
-22.80 (-0.82%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 2870

Today's Low

₹ 2700.75

52 Week High

₹ 3645

52 Week Low

₹ 2213

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 22987.73 Cr.

Enterprise Value

₹ 22387.95 Cr.

No. of Shares

8.36 Cr.

P/E

46.23

P/B

10.77

Face Value

₹ 10

Div. Yield

0.87 %

Book Value (TTM)

₹  255.31

CASH

₹ 683.12 Cr.

DEBT

₹ 83.33 Cr.

Promoter Holding

53.91 %

EPS (TTM)

₹  59.49

Sales Growth

11.18%

ROE

22.09 %

ROCE

27.77%

Profit Growth

31.47 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 24 Indices.

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
45290.75
  -149.050000000003 (-0.328016408522935%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
41288.55
  -394.5 (-0.946427864563648%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
40221.15
  96.25 (0.239875987229876%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
23936.8
  -168.799999999999 (-0.700252223549713%)

NIFTY500

Nifty 500
21675.55
  -167.5 (-0.766834301986219%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17953.75
  -38.4500000000007 (-0.213703716054736%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16256.3
  -87.6500000000015 (-0.536284068416759%)

NIFTYSMALL

NIFTY Smallcap 100
16085.65
  -98.1000000000004 (-0.606163590020858%)

NIFTYSMALLCAP250

Nifty Smallcap 250
15080.45
  -100 (-0.658742000401835%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14882.4
  -96.8000000000011 (-0.646229438154244%)

NFT500EQUAL

Nifty 500 Equal Weight
12786.55
  -50.1000000000004 (-0.390288743558487%)

NIFTYTOTALMCAP

Nifty Total Market index
12168.05
  -91.1000000000004 (-0.743118405435939%)

NIFTYSMALLCAP50

Nifty Smallcap 50
7736.55
  -62.5500000000002 (-0.802015617186602%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
46741.95
  -140.780000000006 (-0.30028114830345%)

BSE HC

S&P Bse Healthcare
41222.6
  -65.3400000000038 (-0.158254444275985%)

BSE500

S&P Bse 500
34105.3
  -234.399999999994 (-0.682591868886429%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
10904.46
  -18.8900000000012 (-0.17293229641091%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

BSE1000

Bse 1000
10119.33
  -66.2999999999993 (-0.650917027223641%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SMLSEL

S&P Bse SmallCap Select Index
6990.05
  -19.9099999999999 (-0.284024445217945%)

SML250

S&P Bse 250 SmallCap
6059.13
  -33.1899999999996 (-0.544784252961095%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.18%
3 Year9.68%
5 Year11.04%

Profit Growth

1 Year31.47%
3 Year11.12%
5 Year14.48%

ROE%

1 Year22.09%
3 Year22.64%
5 Year23.5%

ROCE %

1 Year27.77%
3 Year27.58%
5 Year30.04%

Debt/Equity

0.0451

Price to Cash Flow

48.13

Interest Cover Ratio

20.2268

CFO/PAT (5 Yr. Avg.)

1.29564266453021

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 53.91 0.00
Dec 2024 53.91 0.00
Sep 2024 53.92 0.00
Jun 2024 54.60 0.00
Mar 2024 54.60 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 153.337 Cr.
  • Company has been maintaining healthy ROE of 22.6400976043492% over the past 3 years.
  • Company has been maintaining healthy ROCE of 27.5837463106687% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 20.2268.
  • The Company has been maintaining an effective average operating margins of 26.9646599702361% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -125.7881 days.
  • Company has a healthy liquidity position with current ratio of 2.1688.
  • The company has a good cash flow management; CFO/PAT stands at 1.29564266453021.
  • The company has a high promoter holding of 53.91%.

 Limitations

  • The company has shown a poor revenue growth of 9.68163233722905% for the Past 3 years.
  • The company is trading at a high PE of 46.23.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 520.9 534.5 583.9 528.1 577.2
Total Expenditure 383.3 379 399.4 382.7 418.1
Operating Profit 137.6 155.5 184.5 145.4 159.1
Other Income 16.5 28.8 22 29.5 25.2
Interest 6.3 5.5 5 4.8 4.8
Depreciation 34.6 17.8 18.2 18.9 34.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 113.2 161 183.3 151.2 144.9
Tax 32.4 38.1 48.1 36.7 -3.5
Profit After Tax 80.8 122.9 135.2 114.5 148.4
Adjusted EPS (Rs) 9.67 14.72 16.17 13.7 17.75

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1273.6 1490.56 1878.79 1769.03 1966.76
Total Expenditure 945.79 1083.18 1366.32 1308.33 1407.52
Operating Profit 327.81 407.38 512.47 460.7 559.24
Other Income 57.61 51.27 53.1 46.6 60.11
Interest 14.66 14.83 28.63 34.38 26.84
Depreciation 68.01 69.78 75.94 82.09 76.54
Exceptional Items 0 0 0 0 0
Profit Before Tax 302.75 374.04 460.99 390.83 515.97
Tax 79.57 93.94 115.74 98.47 131.6
Net Profit 223.18 280.11 345.25 292.36 384.37
Adjusted EPS (Rs.) 26.78 33.61 41.42 35.07 46.04

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 83.35 83.35 83.35 83.37 83.48
Total Reserves 932.94 1133.74 1388.77 1606.5 1816.18
Borrowings 0 0 166.67 83.33 0
Other N/C liabilities 68.18 76.83 90.73 82.26 52.71
Current liabilities 211.29 252.25 451.04 432.16 424.44
Total Liabilities 1295.75 1546.16 2180.55 2287.62 2376.81
Assets
Net Block 296.53 300.07 370.95 361.48 308.97
Capital WIP 10.3 5.51 14.45 2.97 3.95
Intangible WIP 0.99 3.48 0 1.97 1.7
Investments 93.88 120.4 1061.81 1072.03 1072.8
Loans & Advances 18.43 23.87 24.33 19.89 19.97
Other N/C Assets 13.21 3.53 9.71 19.11 48.88
Current Assets 862.41 1089.3 699.31 810.17 920.55
Total Assets 1295.75 1546.16 2180.55 2287.62 2376.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 302.75 374.04 460.99 390.83 515.97
Adjustment 45.84 59.1 87.81 96.31 64.29
Changes in Assets & Liabilities 12.57 37.33 -5.55 39.52 22.76
Tax Paid -89.17 -97.12 -117.53 -99.13 -125.42
Operating Cash Flow 271.99 373.36 425.73 427.53 477.6
Investing Cash Flow -19.47 -195.19 -448.53 -288.47 31.91
Financing Cash Flow -187.22 -135.74 141.24 -270.05 -404
Net Cash Flow 65.3 42.42 118.43 -130.99 105.51

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 54.60 54.60 53.92 53.91 53.91
anjaneya lal - 2.02 2.02 2.02 2.02
archana lal erdmann 2.03 2.03 1.85 1.85 1.85
arvind lal - 31.28 30.81 30.80 30.80
vandana lal - 19.26 19.24 19.24 19.24
anjaneya lal 2.02 - - - -
arvind lal 31.28 - - - -
vandana lal 19.27 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 45.40 45.40 46.08 46.09 46.09
hdfc trustee company limi... - 2.99 3.30 2.92 3.23
indus india fund (mauriti... - - - - 1.02
invesco oppenheimer inter... 3.80 3.73 3.56 3.56 3.52
life insurance corporatio... 1.47 1.47 1.47 1.47 1.47
llp 0.03 0.03 0.03 0.02 0.02
nippon life india trustee... - - - - 1.68
sbi large & midcap fund - 1.01 1.76 1.65 1.70
smallcap world fund, inc - - - 1.18 1.47
the brown capital managem... - - - - 1.34
uti-flexi cap fund - - - - 2.32
om prakash manchanda 1.16 1.08 1.04 1.01 -
uti flexi cap fund 3.07 2.82 2.30 2.06 -
first sentier investors i... 1.14 1.10 1.10 - -
al mehwar commercial inve... 1.06 1.02 - - -
wasatch emerging india fu... 1.02 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Lal PathLabs informs about press release 8 May, 5:35 PM Dr. Lal PathLabs informs about newspaper publication 26 Apr, 12:29 PM Dr. Lal PathLabs informs about press release 26 Apr, 12:20 PM Dr. Lal PathLabs informs about AGM 25 Apr, 5:09 PM Dr. Lal Pathlabs - Quaterly Results 25 Apr, 2:20 PM Dr. Lal Pathlabs - Quaterly Results 25 Apr, 2:20 PM Dr. Lal Pathlabs - Quaterly Results 25 Apr, 2:20 PM Dr. Lal PathLabs informs about press release 15 Apr, 2:25 PM Dr. Lal PathLabs launches test for Amyloidosis disease 15 Apr, 12:21 PM Dr. Lal PathLabs informs about trading window closure 25 Mar, 12:25 PM Dr. Lal PathLabs informs about postal ballot notice 7 Feb, 10:40 AM Dr. Lal Pathlabs - Quaterly Results 30 Jan, 1:39 PM Dr. Lal Pathlabs - Quaterly Results 30 Jan, 1:39 PM Dr. Lal Pathlabs - Quaterly Results 30 Jan, 1:39 PM Dr. Lal PathLabs informs about conference call 24 Jan, 12:34 PM Dr. Lal PathLabs informs about allotment under ESOP 18 Dec, 3:19 PM Dr. Lal PathLabs informs about analyst meet 26 Nov, 1:02 PM Dr. Lal Pathlabs - Quaterly Results 23 Oct, 3:38 PM Dr. Lal Pathlabs - Quaterly Results 23 Oct, 3:38 PM Dr. Lal Pathlabs - Quaterly Results 23 Oct, 3:38 PM Dr. Lal PathLabs informs about board meeting 16 Oct, 1:13 PM Dr. Lal PathLabs informs about closure of trading window 26 Sep, 12:54 PM Dr. Lal PathLabs informs about outcome of board meeting 13 Aug, 11:06 AM Dr. Lal PathLabs informs about transcript of earnings call 13 Aug, 11:03 AM Dr. Lal Pathlabs - Quaterly Results 7 Aug, 3:08 PM Dr. Lal Pathlabs - Quaterly Results 7 Aug, 3:08 PM Dr. Lal Pathlabs - Quaterly Results 7 Aug, 3:08 PM Dr. Lal PathLabs submits board meeting intimation 31 Jul, 1:22 PM Dr. Lal PathLabs informs about newspaper advertisements 6 Jun, 3:48 PM Dr. Lal Pathlabs - Quaterly Results 10 May, 1:40 PM Dr. Lal Pathlabs - Quaterly Results 10 May, 1:40 PM Dr. Lal Pathlabs - Quaterly Results 10 May, 1:40 PM Dr. Lal PathLabs informs about board meeting 3 May, 10:49 AM Dr. Lal PathLabs informs about closure of trading window 26 Mar, 2:59 PM Dr. Lal PathLabs informs about outcome of committee meet 18 Mar, 8:16 AM Dr. Lal PathLabs informs about earnings presentation 1 Feb, 3:46 PM Dr. Lal Pathlabs - Quaterly Results 1 Feb, 1:30 PM Dr. Lal Pathlabs - Quaterly Results 1 Feb, 1:30 PM Dr. Lal Pathlabs - Quaterly Results 1 Feb, 1:30 PM Dr. Lal PathLabs informs about conference call 25 Jan, 2:34 PM Dr. Lal PathLabs informs about board meeting 25 Jan, 2:22 PM Dr. Lal PathLabs informs about closure of trading window 25 Jan, 12:34 PM Dr. Lal PathLabs informs about allotment of equity shares under ESOP 17 Nov, 2:30 PM Dr. Lal Pathlabs - Quaterly Results 2 Nov, 1:37 PM Dr. Lal Pathlabs - Quaterly Results 2 Nov, 1:37 PM Dr. Lal Pathlabs - Quaterly Results 2 Nov, 1:37 PM Dr. Lal PathLabs informs about analyst meet 15 Sep, 12:12 PM Dr. Lal PathLabs informs about AGM 17 Aug, 5:16 PM Dr. Lal PathLabs informs about BRSR 17 Aug, 5:10 PM Dr. Lal PathLabs informs about transcript of conference call 2 Aug, 12:53 PM

Dr. Lal Pathlabs Stock Price Analysis and Quick Research Report. Is Dr. Lal Pathlabs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Lal Pathlabs and its performance over the period of time. Dr. Lal Pathlabs stock price today is Rs 2774.4.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dr. Lal Pathlabs cash from the operating activity was Rs 477.599 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Lal Pathlabs has a Debt to Equity ratio of 0.0451 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Lal Pathlabs , the EPS growth was 31.2991 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Lal Pathlabs has OPM of 28.4346116807457 % which is a good sign for profitability.
     
  • ROE: Dr. Lal Pathlabs have a healthy ROE of 22.0871 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dr. Lal Pathlabs is Rs 2774.4. One can use valuation calculators of ticker to know if Dr. Lal Pathlabs share price is undervalued or overvalued.
Last Updated on:
Brief about Dr. Lal Pathlabs

Dr. Lal Pathlabs Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Dr. Lal Pathlabs Ltd. is a leading provider of diagnostic healthcare services in India. Long-term investors interested in investing in healthcare companies need to conduct a comprehensive stock analysis of Dr. Lal Pathlabs Ltd. The analysis should include essential factors like balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Dr. Lal Pathlabs Ltd. Share Price

The share price of Dr. Lal Pathlabs Ltd. is a crucial factor to consider when analyzing the company for long-term investment. The share price is influenced by various factors, including market trends, financial performance, and investor sentiment. Ticker pre-built screening tools provide real-time updates on the share price of Dr. Lal Pathlabs Ltd., helping investors stay informed about price fluctuations and market trends.

Dr. Lal Pathlabs Ltd. Balance Sheet

Analyzing the balance sheet of Dr. Lal Pathlabs Ltd. is essential to understand the financial stability and performance of the company. The balance sheet provides a snapshot of the company's assets, liabilities, and shareholders' equity. Dr. Lal Pathlabs Ltd.'s balance sheet is analyzed using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, allowing investors to calculate fair value based on the balance sheet.

Dr. Lal Pathlabs Ltd. Annual Report

Dr. Lal Pathlabs Ltd. annual report provides comprehensive details about the company's financial performance, strategic initiatives, and future prospects. Investors can access and download the annual report directly from Ticker to gain a deeper understanding of Dr. Lal Pathlabs Ltd.'s performance and make well-informed investment decisions.

Dr. Lal Pathlabs Ltd. Dividend

Dr. Lal Pathlabs Ltd. provides dividends as a way to share its profits with shareholders. Dividends are a crucial consideration for long-term investors, as they demonstrate the company's commitment to returning value to shareholders. By monitoring dividend payments through Ticker pre-built screening tools, investors can stay updated on the latest dividend announcements and assess the company's dividend history.

Dr. Lal Pathlabs Ltd. Quarterly Results

Analyzing the quarterly results of Dr. Lal Pathlabs Ltd. provides crucial information about the company's growth and profitability over specific periods. By monitoring revenue, expenses, and profits, investors can assess the company's performance and make informed investment decisions. Dr. Lal Pathlabs Ltd.'s financial information is analyzed using tools like Earnings multiple approaches and DuPont analysis, enabling long-term investors to make informed investment decisions.

Dr. Lal Pathlabs Ltd. Stock Price

The stock price of Dr. Lal Pathlabs Ltd. is influenced by various factors, including market trends, financial performance, and investor sentiment. Tracking the stock price helps investors gain insights into the market's reaction to the company's performance and news. Ticker pre-built screening tools provide real-time updates on the stock price of Dr. Lal Pathlabs Ltd., allowing investors to stay informed about price movements and make well-informed decisions.

Dr. Lal Pathlabs Ltd. Price Chart

The price chart of Dr. Lal Pathlabs Ltd. visually represents the historical trends of the stock price. By analyzing the chart, long-term investors can identify patterns and trends that may impact future stock performance. The price chart is a valuable tool for assessing the potential investment value of Dr. Lal Pathlabs Ltd. and making informed decisions.

Dr. Lal Pathlabs Ltd. News

Staying updated with the latest news about Dr. Lal Pathlabs Ltd. is crucial for long-term investors conducting a stock analysis. Ticker provides access to the company's news, including press releases, analyst reports, and market updates. This ensures investors can keep track of changes and developments in the company and make informed investment decisions.

Dr. Lal Pathlabs Ltd. Concall

Participating in Dr. Lal Pathlabs Ltd.'s concall allows investors to hear directly from the management team. The concall offers valuable insights into the company's financial performance, strategic initiatives, and future plans. Investors can access the transcripts of the concall on Ticker, enabling them to review and refer to the discussions.

Dr. Lal Pathlabs Ltd. Transcripts

The transcripts of Dr. Lal Pathlabs Ltd.'s concall provide a detailed account of the discussions between the management team, analysts, and investors. These transcripts contain valuable information that aids in investment analysis and decision-making.

Dr. Lal Pathlabs Ltd. Investor Presentations

Dr. Lal Pathlabs Ltd.'s investor presentations provide an in-depth overview of the company's operations, future prospects, and growth strategy. By reviewing these presentations, investors can gain insights into Dr. Lal Pathlabs Ltd.'s long-term plans and evaluate its potential as an investment opportunity.

Dr. Lal Pathlabs Ltd. Promoters

Identifying the promoters of Dr. Lal Pathlabs Ltd. provides insights into the management team's involvement and influence over the company. Understanding the promoters helps in analyzing the company's ownership structure and potential conflicts of interest.

Dr. Lal Pathlabs Ltd. Shareholders

Analyzing the shareholder base of Dr. Lal Pathlabs Ltd. provides investors with insights into the company's ownership structure. Understanding the distribution of shares among various shareholders helps assess its potential impact on the company's stock performance and governance.

Dr. Lal Pathlabs Ltd. ROCE

Dr. Lal Pathlabs Ltd's Return on Capital Employed (ROCE) is a fundamental metric that evaluates the company's profitability and efficiency in utilizing its capital investments. Our stock analysis page offers the ROCE data for Dr. Lal Pathlabs Ltd, enabling investors to assess the company's ability to generate returns on the capital employed. By analyzing this ratio, investors can understand the company's financial performance and make informed investment decisions. Access detailed information on Dr. Lal Pathlabs Ltd's ROCE in the financials table or ratio section on our website.

Dr. Lal Pathlabs Ltd. EBITDA

Dr. Lal Pathlabs Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a crucial measure for assessing the company's operational performance and profitability. By analyzing the company's core earnings, investors gain insights into its financial stability. Our stock analysis page provides comprehensive EBITDA data for Dr. Lal Pathlabs Ltd, allowing investors to evaluate the company's operational efficiency. You can find detailed EBITDA figures for Dr. Lal Pathlabs Ltd in the financials table or ratio section on our website.

Dr. Lal Pathlabs Ltd. DPS

Dr. Lal Pathlabs Ltd's Dividends Per Share (DPS) indicates the portion of profits distributed to shareholders in the form of dividends. Monitoring DPS is essential for investors seeking a consistent dividend income. On our stock analysis page, we present the DPS data for Dr. Lal Pathlabs Ltd, enabling investors to track the company's dividend history and payout ratio. You can find the detailed DPS information in the financials table or ratio section on our website.

Dr. Lal Pathlabs Ltd. EPS

Earnings Per Share (EPS) measures Dr. Lal Pathlabs Ltd's profitability on a per-share basis. By analyzing the company's EPS, investors can assess its earnings performance and growth potential. Our stock analysis page provides comprehensive EPS information for Dr. Lal Pathlabs Ltd, allowing investors to evaluate the company's profitability trends. Access the detailed EPS figures for Dr. Lal Pathlabs Ltd in the financials table or ratio section on our website to make informed investment decisions. 

Dr. Lal Pathlabs Balance Sheet Exploration

Dr. Lal Pathlabs' Sturdy Reserve Growth

The Standalone Balance Sheet of Dr. Lal Pathlabs exhibits a steadfast growth in total reserves, escalating from Rs. 932.94 Cr in March 2020 to Rs. 1,816.18 Cr by March 2024. This progression demonstrates the company's robust financial health and capacity for further expansion or debt reduction.

Effective Debt Management at Dr. Lal Pathlabs

Remarkably, Dr. Lal Pathlabs showcased prudent financial stewardship by clearing its borrowings, which were recorded at Rs. 166.67 Cr in March 2022, down to zero by March 2024. This maneuver evidences the company's strategic financial planning and commitment to operating without leveraging debt.

Asset Augmentation Strategies of Dr. Lal Pathlabs

With total assets amounting to Rs. 2,376.81 Cr by March 2024, Dr. Lal Pathlabs has adeptly matched its liabilities, underscoring its strategic asset growth, particularly in investments which stood at Rs. 1,072.80 Cr, and an uptick in current assets to Rs. 920.55 Cr, ensuring liquidity for operational efficiency.

Insightful Investment in Dr. Lal Pathlabs

The surge in investments to Rs. 1,072.80 Cr by March 2024 highlights Dr. Lal Pathlabs' focus on harnessing market opportunities to bolster long-term growth, reflecting a strategic vision towards enhancing shareholder value.

This analysis on Dr. Lal Pathlabs' Standalone Balance Sheet draws attention to its efficacious financial management, operational efficiency, and strategic investment moves aimed at fostering sustainable growth and stability.

Investors tracking the healthcare sector on NSE and BSE indices may find companies like Dr. Lal Pathlabs particularly intriguing for their consistent financial performance and strategic market positioning.

Read More
X